Moderna posts a promising snapshot of human data for a leading Covid-19 vaccine — and rally makes Bob Langer a billionaire

Stéphane Bancel, Moderna CEO (AP Images)

May 18, 2020 07:32 AM EDTUpdated 02:48 PM

Moderna posts a promising snapshot of human data for a leading Covid-19 vaccine — and rally makes Bob Langer a billionaire

John Carroll

Editor & Founder

Moderna $MRNA just posted some of the most eagerly anticipated human data for a vaccine in modern history. And it’s positive.

The bottom line: Moderna’s mRNA-1273 triggered a therapeutic immune response in 8 patients at the low and mid-dose — 25 μg and 100 μg after a single injection. There were dose-dependent increases in immunogenicity through both doses covering 4 patients in each group, according to Moderna, with patients achieving the same or better level of response seen in recovering patients.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Implementing resilience in the clinical trial supply chain

Nina Vas

Vice President, Clinical Distribution, Cell and Gene Supply Chain

Since January 2020, the clinical trials ecosystem has quickly evolved to manage roadblocks impeding clinical trial integrity, and patient care and safety amid a global pandemic. Closed borders, reduced air traffic and delayed or canceled flights disrupted global distribution, revealing how flexible logistics and supply chains can secure the timely delivery of clinical drug products and therapies to sites and patients.

November 23, 2020 07:27 AM EST

Deals

Coronavirus

In final days at Merck, Roger Perlmutter bets big on a little-known Covid-19 treatment

Jason Mast

Associate Editor

Roger Perlmutter is spending his last days at Merck, well, spending.

Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion, Merck announced today that it had purchased OncoImmune and its experimental Covid-19 drug for $425 million. The drug, known as CD24Fc, appeared to reduce the risk of respiratory failure or death in severe Covid-19 patients by 50% in a 203-person Phase III trial, OncoImmune said in September.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

November 23, 2020 05:43 AM ESTUpdated 02:00 PM

Coronavirus

UPDATED: AstraZeneca, Oxford on the defensive as skeptics dismiss 70% average efficacy for Covid-19 vaccine

Amber Tong

Editor

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Leonard Schleifer, Regeneron CEO (Andrew Harnik/AP)

November 23, 2020 06:32 AM EST

Regulatory

Coronavirus

Trailing Eli Lilly by 12 days, Regeneron gets the FDA OK for their Covid-19 antibody cocktail

Jason Mast

Associate Editor

A month and a half after becoming the experimental treatment of choice for a newly diagnosed president, Regeneron’s antibody cocktail has received emergency use authorization from the FDA. It will be used to treat non-hospitalized Covid-19 patients who are at high-risk of progressing.

Although the Rgeneron drug is not the first antibody treatment authorized by the FDA, the news comes as a significant milestone for a company and a treatment scientists have watched closely since the outbreak began.

Bahija Jallal (file photo)

November 23, 2020 02:00 AM ESTUpdated 06:47 AM

R&D

TCR pioneer Immunocore scores a first with a landmark PhIII snapshot on overall survival for a rare melanoma

John Carroll

Editor & Founder

Bahija Jallal’s crew at TCR pioneer Immunocore says they have nailed down a promising set of pivotal data for their lead drug in a frontline setting for a solid tumor. And they are framing this early interim readout as the convincing snapshot they need to prove that their platform can deliver on a string of breakthrough therapies now in the clinic or planned for it.

In advance of the Monday announcement, Jallal and R&D chief David Berman took some time to walk me through the first round of Phase III data for their lead TCR designed to treat rare, frontline cases of metastatic uveal melanoma that come with a grim set of survival expectations.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bob Nelsen (Photo by Michael Kovac/Getty Images)

November 23, 2020 11:52 AM ESTUpdated 02:51 PM

Startups

Bob Nelsen raises $800M and recruits a star-studded board to build the 'Foxconn' of biotech

Jason Mast

Associate Editor

Bob Nelsen spent his pandemic spring in his Seattle home, talking on the phone with Luciana Borio, the scientist who used to run pandemic preparedness on the National Security Council, and fuming with her about the dire state of American manufacturing.

Companies were rushing to develop vaccines and antibodies for the new virus, but even if they succeeded, there was no immediate supply chain or infrastructure to mass-produce them in a way that could make a dent in the outbreak.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

November 23, 2020 11:14 AM EST

R&D

Amgen severs 14-year Cytokinetics partnership, bailing on omecamtiv after mixed PhIII results

Nicole DeFeudis

Associate Editor

Amgen is shrugging off a 14-year development alliance and the tens of millions of dollars spent to develop a new heart drug at Cytokinetics after a Phase III trial turned up weak data — leaving Cytokinetics to soldier on alone.

Omecamtiv mecarbil technically worked, meeting the primary composite endpoint in the Phase III GALACTIC-HF study. But it missed a key secondary endpoint, which analysts had been following as a key marker for success — reduction of cardiovascular (CV) death. While Cytokinetics celebrated the results, its stock tanked 43% upon the news, and analysts warned of an uncertain path ahead. Now, Amgen wants out.

Carl Hansen, AbCellera CEO (University of British Columbia)

November 23, 2020 08:39 AM EST

IPOs

From a pair of Air Jordans to a $200M-plus IPO, Carl Hansen is crafting an overnight R&D fortune fueled by Covid-19

John Carroll

Editor & Founder

Back in the summer of 2019, Carl Hansen left his post as a professor at the University of British Columbia to go full time as the CEO at a low-profile antibody shop he had founded called AbCellera.

As biotech CEOs go, even after a fundraise Hansen wasn’t paid a whole heck of a lot. He ended up earning right at $250,000 for the year. His compensation package included a loan — which he later paid back — and a pair of Air Jordan tennis shoes. His newly-hired CFO, Andrew Booth, got a sweeter pay packet than that — which included his own pair of Air Jordans.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

November 23, 2020 11:07 AM EST

News Briefing

News briefing: AbbVie partner Teneobio expands tech license with CAR-T player Poseida; Argenx buys PRV from Bayer for $98M

Amber Tong

Editor

Max Gelman

Associate Editor

Teneobio may be best known for its pact with AbbVie and Gilead, but before its big break the bispecific player had licensed its antibodies for a different use: as binders in CAR-T therapies being developed by Poseida.

Now, the biotechs are expanding their partnership, with Poseida exercising four options to deploy Teneobio’s heavy chain only domain antibodies commercially.

The commercial licensing fees remained under wraps, but Teneobio is eligible for $250 million in milestones for these CAR-Ts against undisclosed targets.